<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Spiramycin (United States: Available via FDA or other investigational drug [IND] protocol only): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Spiramycin (United States: Available via FDA or other investigational drug [IND] protocol only): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Spiramycin (United States: Available via FDA or other investigational drug [IND] protocol only): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12005" href="/d/html/12005.html" rel="external">see "Spiramycin (United States: Available via FDA or other investigational drug [IND] protocol only): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52868280"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Rovamycine 250;</li>
<li>Rovamycine 500</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F222759"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Macrolide</li></ul></div>
<div class="block doa drugH1Div" id="F222730"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5dbd1435-0bdd-4962-89f4-5c84ecddc22d">Mild to moderate infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mild to moderate infections:</b>
<b>Oral:</b> 6,000,000 to 9,000,000 units (4 to 6 capsules of Rovamycine “500” per day) in 2 divided doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63e6329d-0035-4c89-ba5f-d4a49395e5f1">Severe infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe infections:</b>
<b>Oral:</b> 12,000,000 to 15,000,000 units (8 to 10 capsules of Rovamycine “500” per day) in 2 divided doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="879a3f59-54be-443b-b029-6bc73973891a">Gonorrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonorrhea:</b>
<b>Oral:</b> 12,000,000 to 13,500,000 units (8 to 9 capsules of Rovamycine “500”) as a single dose. <b>Note:</b> Spiramycin is not a recommended therapy for gonorrhea in clinical practice guidelines (CDC [Workowski 2021]; PHAC 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0905d4bd-32d5-49eb-80b4-a8a57645304e">Toxoplasmosis, vertical transmission prophylaxis, in patients who are pregnant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxoplasmosis, vertical transmission prophylaxis, in patients who are pregnant (off-label use):</b>
<b>Oral:</b> 1 g (3,000,000 units [2 capsules of Rovamycine “500”]) every 8 hours to prevent transmission to fetus. If there is <b>no</b> evidence of transmission to the fetus, spiramycin can be continued until term. <b>Note:</b> If fetal infection has occurred or is suspected, agents other than spiramycin are recommended (HHS [OI adult 2022]; Maldonado 2017; SOGC [Paquet 2018]).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991970"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F222731"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F222743"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dac4e57c-0935-4a97-9247-ad53a6faa20a">Susceptible infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Susceptible infections:</b> Oral: Dosage by body weight; usual dosage 150,000 units/kg; expressed as the number of 750,000 unit (Rovamycine “250”) capsules per day. Daily dose should be administered in 2 to 3 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">15 kg = 3 capsules per day</p>
<p style="text-indent:-2em;margin-left:4em;">20 kg = 4 capsules per day</p>
<p style="text-indent:-2em;margin-left:4em;">30 kg = 6 capsules per day</p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Note:</b> In severe infections, dosage may be increased by 50%.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51160247"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment required.</p></div>
<div class="block adr drugH1Div" id="F222706"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile </i>colitis, diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Henoch-Schönlein purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Paresthesia (transient)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolysis (acute)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (idiosyncratic) (Chalasani 2021)</p></div>
<div class="block coi drugH1Div" id="F222716"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to spiramycin or any component of the formulation; treatment of meningitis.</p></div>
<div class="block war drugH1Div" id="F222704"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Altered cardiac conduction: Macrolides have been associated with rare QT<sub>c</sub> prolongation and ventricular arrhythmias, including torsade de pointes; use with caution in patients at risk of prolonged cardiac repolarization.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hepatic impairment: Use with caution in patients with pre-existing liver disease; hepatic impairment, including hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been observed. Discontinue if symptoms of malaise, nausea, vomiting, abdominal colic, and fever.</p></div>
<div class="block prod-avail drugH1Div" id="F11234333"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040742"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52868281"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rovamycine 250: 750,000 units [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rovamycine 500: 1,500,000 units</p></div>
<div class="block accres drugH1Div" id="F50509528"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Spiramycin is not commercially available in the US; it is available for treatment of toxoplasmosis in pregnant women through the US Food and Drug Administration (301-796-1400).</p></div>
<div class="block adm drugH1Div" id="F9614171"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without regard to meals; however, administration during a meal may improve GI tolerance (Peyron 2019).</p></div>
<div class="block admp drugH1Div" id="F52750111"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to meals.</p></div>
<div class="block use drugH1Div" id="F222714"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">Treatment of infections of the respiratory tract, buccal cavity, skin, and soft tissues due to susceptible organisms; as an alternative agent for gonorrhea in patients allergic to the penicillins. <b>Note:</b> Spiramycin is not a recommended therapy for gonorrhea in clinical practice guidelines (CDC [Workowski 2021]; PHAC 2021).</p></div>
<div class="block off-label drugH1Div" id="F25744911"><span class="drugH1">Use: Off-Label: Adult</span><p>Toxoplasmosis, vertical transmission prophylaxis, in patients who are pregnant</p></div>
<div class="block cyt drugH1Div" id="F222753"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F222708"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbidopa: Spiramycin may decrease the serum concentration of Carbidopa. And thus may decrease the effectiveness of levodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mizolastine: Macrolide Antibiotics may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F222719"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Spiramycin concentrates in the placenta; fetal exposure is limited (Couvreur 1993; Gratzl 2002; Montoya 2008).</p>
<p style="text-indent:0em;margin-top:2em;">Spiramycin is not considered to be teratogenic (HHS [OI adult] 2022; Maldonado 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Spiramycin is used off label for the management of acute toxoplasmosis and reactivated latent toxoplasmosis in pregnant patients to prevent fetal infection. Maternal infection may be asymptomatic; however, congenital transmission may occur. Fetal <i>Toxoplasma gondii </i>infection can lead to adverse outcomes such as chorioretinitis, visual impairment, hearing loss, and/or developmental delay in the newborn. The risk of fetal infection increases with gestational age; however, congenital disease severity increases the earlier in gestation the fetal infection occurs (ACOG 2015; HHS [OI adult] 2022; SOGC [Paquet 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal treatment with spiramycin is recommended to prevent congenital transmission when maternal infection is diagnosed prior to fetal infection. Spiramycin does not cross the placenta in concentrations to treat the fetus; if fetal infection has occurred, agents other than spiramycin are recommended. Amniotic fluid testing, when needed for fetal diagnosis, should be avoided prior to 18 weeks’ gestation to minimize the possibility of false-negative results. Monthly fetal monitoring is recommended during spiramycin therapy (ACOG 2015; HHS [OI adult] 2022; SOGC [Paquet 2018]).</p></div>
<div class="block dic drugH1Div" id="F222721"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Food may improve gastrointestinal tolerance.</p></div>
<div class="block pha drugH1Div" id="F222703"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits growth of susceptible organisms; mechanism not established.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F222722"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Rovamycin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Rovamicina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Acetylspiramycin | Yi nuo xin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Selectomycin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dicorvin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dicorvin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Acetyl Spiramycin | Hypermycin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Rovamycine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26000539">
<a name="26000539"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 151: Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. <i>Obstet Gynecol</i>. 2015;125(6):1510-1525. doi:10.1097/01.AOG.0000466430.19823.53<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/26000539/pubmed" id="26000539" target="_blank">26000539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966. doi:10.1038/ajg.2014.131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8452648">
<a name="8452648"></a>Couvreur J, Thulliez P, Daffos F, et al. In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine. <i>Fetal Diagn Ther</i>. 1993;8(1):45-50. doi:10.1159/000263746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/8452648/pubmed" id="8452648" target="_blank">8452648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3336419">
<a name="3336419"></a>Daffos F, Forestier F, Capella-Pavlovsky M, et al. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. <i>N Engl J Med</i>. 1988;318(5):271-275. doi:10.1056/NEJM198802043180502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/3336419/pubmed" id="3336419" target="_blank">3336419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11913495">
<a name="11913495"></a>Gratzl R, Sodeck G, Platzer P, et al. Treatment of toxoplasmosis in pregnancy: concentrations of spiramycin and neospiramycin in maternal serum and amniotic fluid. <i>Eur J Clin Microbiol Infect Dis</i>. 2002;21(1):12-16. doi:10.1007/s10096-001-0644-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/11913495/pubmed" id="11913495" target="_blank">11913495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2681638">
<a name="2681638"></a>Hohlfeld P, Daffos F, Thulliez P, et al. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. <i>J Pediatr</i>. 1989;115(5, pt 1):765-769. doi:10.1016/s0022-3476(89)80660-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/2681638/pubmed" id="2681638" target="_blank">2681638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28138010">
<a name="28138010"></a>Maldonado YA, Read JS; Committee on Infectious Diseases. Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. <i>Pediatrics</i>. 2017;139(2):e20163860. doi:10.1542/peds.2016-3860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/28138010/pubmed" id="28138010" target="_blank">28138010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18624630">
<a name="18624630"></a>Montoya JG, Remington JS. Management of <i>Toxoplasma gondii</i> infection during pregnancy. <i>Clin Infect Dis</i>. 2008;47(4):554-566. doi:10.1086/590149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/18624630/pubmed" id="18624630" target="_blank">18624630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30103893">
<a name="30103893"></a>Paquet C, Yudin MH. No. 285-Toxoplasmosis in pregnancy: prevention, screening, and treatment. <i>J Obstet Gynaecol Can</i>. 2018;40(8):e687-e693. doi:10.1016/j.jogc.2018.05.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/30103893/pubmed" id="30103893" target="_blank">30103893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30781652">
<a name="30781652"></a>Peyron F, L'ollivier C, Mandelbrot L, et al. Maternal and congenital toxoplasmosis: diagnosis and treatment recommendations of a French multidisciplinary working group. <i>Pathogens</i>. 2019;8(1):24. doi:10.3390/pathogens8010024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/30781652/pubmed" id="30781652" target="_blank">30781652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PHAC.1">
<a name="PHAC.1"></a>Public Health Agency of Canada. Gonorrhea guide: key information and resources. <a href="https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/gonorrhea.html" target="_blank">https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/gonorrhea.html</a>. Updated November 9, 2021. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference">
                  Rovamycine (spiramycin) [product monograph]. Quebec, Canada: Aventis Pharma Inc; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2020">
<a name="HHS.2020"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Accessed February 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10092 Version 156.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
